Safety Profile of Durvalumab (D) as Consolidation Treatment (tx) in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) in ADRIATIC: Focus on Pneumonitis and Immune-Mediated Adverse Events (imAEs)

P Iyengar,I Okamoto,Y Chen,H Gowda,K Laktionov,A Shi,Y Ohe,E Buchmeier,M Özgüroğlu,K.H Lee,Y Cheng,D Spigel,S Senan,P Chugh,R Bernabe,A Badzio,S Lu,B.C Cho,N Villanueva Palicio,B Gill

doi:10.1016/j.ijrobp.2024.08.024

Safety Profile of Durvalumab (D) as Consolidation Treatment (tx) in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) in ADRIATIC: Focus on Pneumonitis and Immune-Mediated Adverse Events (imAEs)

P Iyengar, I Okamoto + Show 18 more

https://doi.org/10.1016/j.ijrobp.2024.08.024

Copy DOI

Export

Save

Cite

Journal: International Journal of Radiation Oncology, Biology, Physics

Publication Date: Sep 27, 2024

#Limited-Stage Small-Cell Lung Cancer #Immune-Mediated Adverse Events #Consolidation Treatment #Treatment In Lung Cancer #Treatment In Cancer #Small-Cell Lung Cancer #Safety Profile #Lung Cancer #Adverse Events

Abstract
Full-Text
Similar Papers

Abstract

Listen

Safety Profile of Durvalumab (D) as Consolidation Treatment (tx) in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) in ADRIATIC: Focus on Pneumonitis and Immune-Mediated Adverse Events (imAEs)

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: International Journal of Radiation Oncology, Biology, Physics

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Safety Profile of Durvalumab (D) as Consolidation Treatment (tx) in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) in ADRIATIC: Focus on Pneumonitis and Immune-Mediated Adverse Events (imAEs)